WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

The Department of Justice is requiring Reddy Ice LLC to divest assets across five states to resolve antitrust concerns from its planned acquisition of an ice maker backed by private equity firm ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

HYDERABAD, Jan 21 (Reuters) - Indian drugmaker Dr Reddy's (REDY.NS), opens new tab, which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval ...

Beginning in 2026, the ACC's Distinguished Award for International Service will be named in honor of Navin C. Nanda, MD, FACC, thanks to the support of the American Association of Cardiologists of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

What are music’s biggest global artist stories of 2025? Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and ...

US semiconductor company Marvell Technology has announced plans to significantly increase its workforce and research spending in India, aiming to meet the surging global demand for AI infrastructure.

Marvell Technology, Inc. (NASDAQ: MRVL) is betting on India to unlock long-term value, expanding local talent and innovation as it chases growth in the booming artificial intelligence infrastructure ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...